Ambys Medicines
Paul Kwo, M.D. is a Professor of Medicine and Director of Hepatology at Stanford University where he joined the faculty in November 2016. Prior to joining the faculty at Stanford, he was at Indiana University for 21 years where he served as the Medical Director of Liver Transplantation. Paul has distinguished himself in the field of Hepatitis C therapeutics and has been the principal investigator in multiple international trials. He recently authored the ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries.
Paul received his medical education from Wayne State University School of Medicine and was a resident at the University of Maryland Medical Center. He then completed his fellowship at the Mayo Clinic. Paul is board certified in Gastroenterology and Transplant Hepatology, both by the American Board of Internal Medicine.
This person is not in the org chart
This person is not in any offices
Ambys Medicines
Ambys Medicines is a biotechnology company focused on discovering and developing regenerative and restorative therapies for people with advanced liver disease. Founded by world-renowned experts in liver disease and regenerative medicine, Ambys is pioneering the application of novel modalities including cell and gene therapy, and gain-of-function drug therapy, to meet the urgent need for treatments that have the potential to restore liver function and prevent the progression to liver failure across multiple liver diseases that are untreatable or poorly treated today.